Sponsored by
Researchers used data from the French national data health data system for 18,061 women who underwent intracranial meningioma surgery from 2009-2018, and compared them to matched controls. After controlling for confounding factors, they found increased risk of meningioma associated with prolonged use (a year or more) of the following hormone drugs: 2.7 fold increased risk with promegestone; 4.1-fold increased risk with medrogestone, and; 5.6-fold increased risk with medroxyprogesterone acetate. We can't draw definitive conclusions from an observational study, but this is still important information for women weighing oral contraceptive and hormone replacement therapy options.